Boosting of Mucosal Immunity After Fractional-Dose Inactivated Poliovirus Vaccine
| العنوان: | Boosting of Mucosal Immunity After Fractional-Dose Inactivated Poliovirus Vaccine |
|---|---|
| المؤلفون: | Sunethra Gunasena, M. Steven Oberste, Ondrej Mach, William C. Weldon, Paba Palihawadana, Yiting Zhang, Deepa Gamage, Roland W. Sutter |
| المصدر: | The Journal of Infectious Diseases. 218:1876-1882 |
| بيانات النشر: | Oxford University Press (OUP), 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Male, 0301 basic medicine, education, Administration, Oral, Antibodies, Viral, medicine.disease_cause, behavioral disciplines and activities, law.invention, Feces, 03 medical and health sciences, 0302 clinical medicine, Immune system, Randomized controlled trial, law, Immunity, mental disorders, Humans, Immunology and Allergy, Medicine, 030212 general & internal medicine, Viral shedding, Child, Immunity, Mucosal, Immunization Schedule, Sri Lanka, biology, business.industry, Poliovirus, social sciences, Antibodies, Neutralizing, Virology, Virus Shedding, Vaccination, Poliovirus Vaccine, Inactivated, 030104 developmental biology, Infectious Diseases, biology.protein, Inactivated Poliovirus Vaccine, population characteristics, Female, Antibody, business, Poliomyelitis |
| الوصف: | Background Inactivated poliovirus vaccine (IPV) boosts mucosal immunity in persons previously vaccinated with oral poliovirus vaccine (OPV). We assessed whether fractional-dose IPV (fIPV, 1/5th of full dose) administered intradermally also boosts mucosal immunity. Methods Children 10-12 years old were enrolled in Sri Lanka and randomized to receive one dose IPV, fIPV, or no IPV vaccine. One month later, they received OPV challenge. Blood was collected at enrolment and before challenge; stool was collected at 3, 7, and 14 days post-challenge. Sera were analysed for presence of poliovirus neutralizing antibodies; stool was analysed for poliovirus. Results We analysed 304/309 (98%) enrolled subjects. There were 16/97 (16%), 9/99 (9%), and 72/95 (76%) subjects excreting poliovirus after challenge in the IPV, fIPV and "No IPV Vaccine" study arms, respectively (P < .001 for comparison of IPV [or fIPV] vs "No IPV Vaccine"; P = .1 for comparisons of fIPV vs IPV). Relative decrease in excretion prevalence was 80% and 88% to IPV and fIPV, respectively, compared with the "No IPV Vaccine" control arm. Conclusions Single fIPV dose boosted mucosal immunity to a similar degree as single full dose of IPV. This finding provides further evidence in support of fIPV for poliovirus outbreak response at the time of IPV global supply shortage. Clinical trials registration Australia New Zealand Clinical Trial Registry ACTRN12616000124437p. |
| تدمد: | 1537-6613 0022-1899 |
| DOI: | 10.1093/infdis/jiy389 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d8fbb93e8a89987eecd4dc399958016 https://doi.org/10.1093/infdis/jiy389 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....8d8fbb93e8a89987eecd4dc399958016 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15376613 00221899 |
|---|---|
| DOI: | 10.1093/infdis/jiy389 |